skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Tetramethylpyrazine ameliorates experimental autoimmune encephalomyelitis by modulating the inflammatory response

Journal Article · · Biochemical and Biophysical Research Communications
 [1];  [2];  [1]; ;  [3];  [1]
  1. Department of Histology and Embryology, Binzhou Medical University, Yantai (China)
  2. Department of Critical Care Medicine, Yu Huang Ding Hospital, Qingdao University, Yantai (China)
  3. Department of Pathology, Binzhou Medical University, Yantai (China)

Highlights: • TMP improves clinical scores in EAE mice. • TMP decreases demyelination in EAE mice. • TMP reduces inflammatory infiltration and glial activation in EAE mice. • TMP reduces NLRP3 inflammasome expression and modulates the Th1/Th17/Th2 response. Multiple sclerosis (MS) is a disabling inflammatory and demyelinating disorder of the central nervous system. Tetramethylpyrazine (TMP) has been demonstrated to ameliorate cerebral ischemic injury and spinal cord injury by inhibiting inflammatory cell activation and pro-inflammatory cytokine production. However, the effects of TMP on MS have not been studied. In this study, we evaluated the effects of TMP on the inflammatory response in experimental autoimmune encephalomyelitis (EAE), which is an animal model of MS. TMP (30 mg/kg) treatment significantly reduced the expression levels of NLR Family, Pyrin Domain-Containing 3 Protein inflammasome and caspase-1and decreased inflammatory infiltration and glial activation. Moreover, TMP (30 mg/kg) suppressed the expression of pro-inflammatory cytokines (interleukin-18 [IL-18] and IL-17) and promoted the expression of an anti-inflammatory cytokine (IL-10). The reduced inflammatory response resulted in improvement in clinical scores and decreased demyelination in EAE mice. Therefore, our results demonstrate that TMP (30 mg/kg) improved functional recovery in part by reducing inflammation in EAE mice. TMP may be a potential therapeutic agent for MS therapy.

OSTI ID:
23134319
Journal Information:
Biochemical and Biophysical Research Communications, Vol. 503, Issue 3; Other Information: Copyright (c) 2018 Elsevier Inc. All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0006-291X
Country of Publication:
United States
Language:
English

Similar Records

Suppression of NLRP3 inflammasome attenuates stress-induced depression-like behavior in NLGN3-deficient mice
Journal Article · Sun Jul 15 00:00:00 EDT 2018 · Biochemical and Biophysical Research Communications · OSTI ID:23134319

CPT-11 activates NLRP3 inflammasome through JNK and NF-κB signalings
Journal Article · Tue Dec 01 00:00:00 EST 2015 · Toxicology and Applied Pharmacology · OSTI ID:23134319

Critical role of nucleotide-binding oligomerization domain-like receptor 3 in vascular repair
Journal Article · Fri Aug 05 00:00:00 EDT 2011 · Biochemical and Biophysical Research Communications · OSTI ID:23134319